Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma

Haematologica. 2017 May;102(5):e199-e202. doi: 10.3324/haematol.2016.159087. Epub 2017 Feb 2.

Morteza Bashash^{1

2}, Joseph M Connors^{3

4}, Randy D Gascoyne^{5

4}, Barbara Meissner⁴, Johanna M Schuetz⁶, Stephen Leach¹, Graham W Slack^{5

4}, Brian R Berry⁷, Howard Hu², Laurie H Sehn^{3

4}, Angela R Brooks-Wilson^{6

7

8}, John J Spinelli^{9

10}

¹ Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
² Dalla Lana School of Public Health, University of Toronto, ON, Canada.
³ Division of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada.
⁴ Department of Lymphoid Cancer Research, BC Cancer Agency, Vancouver, BC, Canada.
⁵ Department of Pathology, BC Cancer Agency, Vancouver, BC, Canada.
⁶ Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
⁷ Department of Pathology, Royal Jubilee Hospital, Victoria, BC, Canada.
⁸ Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
⁹ Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada jspinelli@bccrc.ca.
¹⁰ School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.

No abstract available

Publication types